Ariad Pharmaceuticals (NASDAQ: ARIA ) will report Q3 results on November 5 before the open. The conference call will begin at 8:30 am ET. Consensus view is a loss of ($0.30) on revenues of $16.5M. Post your comment!
completes its review of the benefits and risks of Ariad Pharmaceuticals ' (NASDAQ: ARIA ) Iclusig (ponatinib). Specifically, it examined ..... healthcare professionals the latest evidence. ARIA shares are up 2% premarket on average volume
LONDON, Oct 10 (Reuters) - European regulators said on Friday the benefits of Ariad Pharmaceuticals ' leukaemia medicine Iclusig continued to outweigh its risks, but called for strengthened warnings on the product.
Privately-held Bellicum Pharmaceuticals pays Ariad Pharmaceuticals ( ARIA ) $50M for a f ull license to Ariad's cell-signalling technology. Under the terms of the revised agreement, Ariad will receive
This Stock Become Painful for Investors? Earlier in the year I wrote an article 'Why Now Is The Time To Buy Ariad Pharmaceuticals ' and highlighted the potential of this small cap biotech company. I believed Ariad was in the beginning of a
Oct 2 (Reuters) - Ariad Pharmaceuticals Inc said its experimental lung cancer drug was granted "breakthrough therapy" status by the U.S. Food and Drug Administration and it expected to file for marketing approval in early 2016.
The FDA designates Ariad Pharmaceuticals ' (NASDAQ: ARIA ) investigational cancer drug, AP26113 , a Breakthrough Therapy for the treatment of patients with anaplastic lymphoma kinase
Oct 2 (Reuters) - Ariad Pharmaceuticals Inc said its experimental lung cancer drug received "breakthrough therapy" status from the U.S. Food and Drug Administration, sending its shares up 7 percent...
Nov 1 (Reuters) - Ariad Pharmaceuticals Inc adopted a shareholder rights plan to protect its tax credits, a day after sales of its flagship drug Iclusig were suspended due to safety concerns...
(Reuters) - Ariad Pharmaceuticals ' shares fell 3 percent on Wednesday morning after a U.S. Food and Drug Administration panel did not recommend the company's experimental cancer candidate.